Why Generation Bio Shares Are Trading Higher Today
Generation Bio (NASDAQ: GBIO) shares are trading higher on Thursday after the company and Moderna (NASDAQ: MRNA) announced a collaboration to develop non-viral genetic medicines.
Reuters Reported Earlier: Vaccine Makers, Including GSK, Moderna, Sanofi Developing Bird Flu Shots For Humans
https://www.reuters.com/business/healthcare-pharmaceuticals/vaccine-makers-prep-bird-flu-shot-humans-just-case-rich-nations-lock-supplies-2023-03-20/
This Is What Whales Are Betting On Moderna
A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking…
Did Elon Musk Just Put His Skepticism Behind And Warm Up To mRNA Tech That Powers Most COVID-19 Vaccines?
Tesla CEO Elon Musk has been a skeptic of the COVID-19 vaccines and highly critical of Dr.
What 13 Analyst Ratings Have To Say About Moderna
Over the past 3 months, 13 analysts have published their opinion on Moderna (NASDAQ:MRNA) stock. These analysts are…
TD Cowen Upgrades Moderna to Outperform, Raises Price Target to $180
TD Cowen analyst Tyler Van Buren upgrades Moderna (NASDAQ:MRNA) from Market Perform to Outperform and raises the price target from $150 to $180.
FDA’s Regulatory Delay is The Reason For Novavax, Lucira Health’s Failure: WSJ Report
Failures of Covid vaccine maker Novavax Inc (NASDAQ: NVAX) and diagnostic start-up Lucira Health Inc (NASDAQ: LHDX) show that companies often succeed or fail, owing to the whims of the government.&nb
How Much Did US Government Spend On mRNA Vaccine Technology Before And During The Pandemic? The Number Can Be Surprising
The U.S. government invested at least $31.9 billion to develop, produce, and purchase mRNA COVID-19 vaccines, including sizeable…
Why This Moderna Analyst Is Very Bullish
Shares of Moderna Inc (NASDAQ: MRNA) have lost almost 24% year to date.
While the prospects of the Covid-vaccine seem to be waning, data from the cancer vaccine is impressive, according to RBC Capital Markets.
RBC Capital Initiates Coverage On Moderna with Outperform Rating, Announces Price Target of $200
RBC Capital analyst Luca Issi initiates coverage on Moderna (NASDAQ:MRNA) with a Outperform rating and announces Price Target of $200.